Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide
Study sponsor: Mirum Pharmaceuticals, Inc. · MIRM
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2027-08-31Estimated
Enrollment · participants120Estimated
Source updated2026-10-27Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.